Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Anthem (ANTM) Q2 Earnings: Is a Beat in Store for the Stock?

2018-07-20 zacks
Anthem Inc. (ANTM - Free Report) will release second-quarter 2018 results on Jul 25 before the market opens. In first-quarter 2018, the company delivered a positive earnings surprise of 12%, led by strong medical cost performance. Let’s see, how things are shaping up for this announcement. Anthem’s revenues have been rising over the past few quarters. We expect revenue growth in the to-be-reported quarter, driven by higher premium revenues in its Government Business segment and to a lesser extent, higher administrative fee revenues in its Commercial & Specialty Business segment.
ATHTF CNC MOH WCG ANTM IQV ANTX

15
Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?

2018-07-20 zacks
Express Scripts Holding Company (ESRX - Free Report) is scheduled to report second-quarter 2018 results on Aug 1, after the market closes. Solid performance by the Pharmacy Benefit Management segment (“PBM”) is likely to drive the company’s top line. However, the company is getting acquired by Cigna Corporation by the end of 2018.
ATHTF BIO.B BIO KDP DXCM WBA BAX ANTM CI ANTX

0
Trump Administration Preparing Fix for Obamacare Risk Payments - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF CNC MOH ANTM ANTX

1
HHS Secretary Tries to Reset Agenda Amid Family-Separations Furor - WSJ

2018-07-18 wsj
Health and Human Services Secretary Alex Azar, whose department has recently become entangled in the fight over separating undocumented children from their families, is pushing to keep focus on his agenda.
ATHTF PFZ ANTM 500680 PFE PFIZER ANTX

19
Why Dip in UnitedHealth Stock Post Q2 is a Good Entry Point

2018-07-18 zacks
UnitedHealth Group Inc. (UNH - Free Report) maintained its trend of surpassing estimates once again, with second-quarter earnings beating by 3.63%.
ATHTF GEC GE WCG GNE ANTM HUM UNH ANTX

10
UnitedHealth second quarter medical costs miss estimates, shares slide

2018-07-17 channelnewsasia
UnitedHealth Group Inc , the largest U.S. health insurer, reported a rise of nearly 28 percent in quarterly profit on Tuesday, driven by growth across its businesses.
ATHTF ANTM CI HUM UNH ANTX

8
How Will Membership Affect UnitedHealth's (UNH) Q2 Earnings?

2018-07-16 zacks
UnitedHealth Group Inc.’s (UNH - Free Report) second-quarter earnings should be partially offset by a decline in enrollment or the number of customers served in the second quarter. Going by the Zacks Consensus Estimate, total medical membership should be 48.89 billion members, down 1.2% year over year.
ATHTF NTRS GTT NTRSP ANTM HUM AET UNH ANTX

4
Centene (CNC) Hits 52 Week High: Is Further Upside Left?

2018-07-06 zacks
On Jul 5, Centene Corp.’s (CNC - Free Report) shares hit a 52 week high of $128.02, ending the day a tad lower at $128.00.
ATHTF CNC MHMI ANTM HUM UNH ANTX

0
Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio

2018-07-03 globenewswire
AUDUBON, Pa., July 03, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today the expansion of its orthopedic trauma product portfolio with two new product offerings, the ANTHEM® Ankle Fracture System and the ANTHEM® Proximal Humerus Fracture System, marking the Trauma division’s fourth and fifth comprehensive product launches over the last 10 months.
ATHTF GMED ANTM ANTX

0
Visited northeast Calgary lately? There's so much new development, you might not recognize it

2018-07-03 cbc.ca
You might not know it, and you likely haven't seen it, but northeast Calgary is changing.
ATHTF AFY

93
Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed

2018-06-29 zacks
Chicago, IL – June 29, 2018 - Stocks in this week’s article Anthem Inc. (ANTM - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) , Boston Scientific Corp. (BSX - Free Report) , Grand Canyon Education, Inc. (LOPE - Free Report) and PetMed Express, Inc. (PETS - Free Report) .
ATHTF RYAM LOPE MMSI WLL RL WCG ANTM RYAM.PRA GIII BSX PETS PII ANTX

43
How Much Is Equinox Gold's Copper Arm Worth?

2018-06-28 seekingalpha
Warintza and La Verde hold 3.7 billion pounds of copper in the measured and indicated category and another 4.6 billion pounds of copper in the inferred category.
ATHTF ABX NCA AOZ EQXGF LGC LWLCF TECK CTMQF GMN CCY CATXF TCKRF LGCUD LGCUF AFY JDL ABX

87
7 GARP Stocks to Scoop Up for Maximum Returns

2018-06-28 zacks
If you’re looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy. It helps an investor gain exposure to stocks that are undervalued and have impressive growth prospects. However, one should not confuse GARP investing with the blend strategy. While the blend strategy promotes investment in both value and growth stocks, GARP investing requires both value and growth features in a single stock.
ATHTF LOPE MMSI BSX PETS ANTM VMW APTV ANTX

132
Sky-High Deductibles Broke the U.S. Health Insurance System - Bloomberg

2018-06-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF BRK.A CCV.CL CCV CMCSA CCZ ANTM CVS CMCSK ANTX

162
Amazon-Berkshire-JPMorgan Health Venture Takes Aim at Middlemen - Bloomberg

2018-06-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
ATHTF BRK.A ANTM CI CVS AET UNH ANTX

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 03675A105